Arcus Biosciences, Inc. (RCUS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Is Arcus Biosciences, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Arcus Biosciences, Inc. (RCUS) trades at $18.19 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Arcus Biosciences, Inc.
Market cap $2B · 52 weeks $18 – $32 (42 % below the high) · P/E no earnings · Dividend none · Next earnings November 4, 2026 · expected EPS $-0.89 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/Sales 1.9× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 4 of 4 pass
- Cash Runway 24 meses, passes, near the threshold.
- Total Debt 0.1×, passes.
- R&D / Market cap 26.8 %, passes.
- Market cap / Cash 2.0×, passes.
- Annual cash burn $4.49, info.
Against its peers (reference peers) — Arcus Biosciences, Inc.: P/E —; EV/EBITDA —; ROIC -65.8 %; $2.3B. Liquidia Corporation (P/E 32.9×; EV/EBITDA 21.8×; ROIC 46.9 %; $4.0B), Harmony Biosciences Holdings, Inc. (P/E 12.6×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.3B), Aurinia Pharmaceuticals Inc. (P/E 7.3×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.2B).
Profitability
| Return on Equity | -87.98% |
| Return on Invested Capital | -65.76% |
| Return on Assets | -48.92% |
| Gross Margin | 94.02% |
| Operating Margin | -415.38% |
| Net Margin | -386.32% |
Financial Health
| Debt / Equity | 0.25 |
| Current Ratio | 3.82 |
| Piotroski F-Score | 0 |
| Altman Z-Score | 1.11 |
Price Performance
| 1 month | -27.90% |
| 3 months | -35.47% |
| Year-to-date | -23.67% |
| 1 year | -7.76% |
| 3 years | +14.98% |
| 5 years | -46.66% |
Related companies: IBRX · COGT · LQDA · DNLI · BEAM · VRDN
Explore sector: Healthcare · Biotechnology
More sections of RCUS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks